Abstract
Oral Cladribine Delays Time to Conversion to Clinically Definite MS in Patients with a First Demyelinating Event: Top Line Results from the Phase III ORACLE MS Study (P07.114)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
